Therapie des kardiogenen Schocks: Was ist belegt?

Zusammenfassung

Im Rahmen dieses Artikels werden die Pathophysiologie, die Inzidenz, das derzeitige Überleben und die Behandlungsoptionen von Patienten mit kardiogenem Schock im Rahmen eines akuten Myokardinfarktes dargelegt. Ein wesentliches Augenmerk wird hierbei auf die derzeitige Evidenz basierend auf randomisierten Studien und die derzeitigen Leitlinienempfehlungen für die Therapie des kardiogenen Schocks gelegt.

Abstract

This review will address the pathophysiology, incidence, current outcome and treatment options of patients with cardiogenic shock complicating acute myocardial infarction. The major focus will be on the current evidence based on randomized clinical trials and the current guideline recommendations for the treatment of cardiogenic shock.

Schlüsselwörter

kardiogener Schock - Myokardinfarkt - Revaskularisation - Prognose - Kreislaufunterstützung

Keywords

cardiogenic shock - myocardial infarction - revascularisation - prognosis - circulatory support

• Literatur

• 1 Aissaoui N, Puymirat E, Tabone X et al. Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French Nationwide Registries. Eur Heart J 2012; 33: 2535-2543
• 2 Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary. Circulation 2004; 110: 588-636
• 3 Awad HH, Anderson Jr FA, Gore JM et al. Cardiogenic shock complicating acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events. Am Heart J 2012; 163: 963-971
• 4 Bauer T, Zeymer U, Hochadel M et al. Use and outcomes of multivessel percutaneous coronary intervention in patients with acute myocardial infarction complicated by cardiogenic shock (from the EHS-PCI Registry). Am J Cardiol 2012; 109: 941-946
• 5 Beurtheret S, Mordant P, Paoletti X et al. Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). Eur Heart J 2013; 34: 112-120
• 6 Cavender MA, Milford-Beland S, Roe MT et al. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol 2009; 104: 507-513
• 7 Cheng JM, den Uil CA, Hoeks SE et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J 2009; 30: 2102-2108
• 8 De Backer D, Biston P, Devriendt J et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362: 779-789
• 9 De Luca L, Colucci WS, Nieminen MS et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006; 27: 1908-1920
• 10 Goldberg RJ, Spencer FA, Gore JM et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009; 119: 1211-1219
• 11 Hamm CW, Bassand J-P, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32: 2999-3054
• 12 Hochman JS, Buller CE, Sleeper LA et al. Cardiogenic shock complicating acute myocardial infarction – etiologies, management and outcome: a report from the SHOCK Trial Registry. J Am Coll Cardiol 2000; 36: 1063-1070
• 13 Hochman JS, Sleeper LA, Webb JG et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625-634
• 14 Jeger RV, Radovanovic D, Hunziker PR et al. Ten-year incidence and treatment of cardiogenic shock. Ann Intern Med 2008; 149: 618-626
• 15 Mehta RH, Lopes RD, Ballotta A et al. Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease?. Am Heart J 2010; 159: 141-147
• 16 O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-e425
• 17 Sjauw KD, Engstrom AE, Vis MM et al. A systematic review and meta-analysis of intra aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?. Eur Heart J 2009; 30: 459-468
• 18 Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619
• 19 Thiele H, Allam B, Chatellier G et al. Shock in acute myocardial infarction: the Cape Horn for trials?. Eur Heart J 2010; 31: 1828-1835
• 20 Thiele H, Schuler G. Cardiogenic shock: To pump or not to pump?. Eur Heart J 2009; 30: 389-390
• 21 Thiele H, Schuler G, Neumann FJ et al. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J 2012; 163: 938-945
• 22 Thiele H, Zeymer U, Neumann FJ et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287-1296
• 23 Tousek P, Rokyta R, Tesarova J et al. Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study. Acute Card Care 2011; 13: 116-122
• 24 Urban P, Stauffer JC, Bleed D et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J 1999; 20: 1030-1038
• 25 Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945
• 26 van der Schaaf RJ, Claessen BE, Vis MM et al. Effect of multivessel coronary disease with or without concurrent chronic total occlusion on one-year mortality in patients treated with primary percutaneous coronary intervention for cardiogenic shock. Am J Cardiol 2010; 105: 955-959
• 27 Webb JG, Lowe AM, Sanborn TA et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol 2003; 42: 1380-1386
• 28 Werdan K, Ruß M, Buerke M et al. Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment – A German-Austrian S3 Guideline. Dtsch Arztebl Int 2012; 109: 343-351
• 29 Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-2555
• 30 Zeymer U, Vogt A, Zahn R et al. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI). Eur Heart J 2004; 25: 322-328